Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Podcasts|May 1, 2022
The Cutaneous Connection: Melanoma Monday: What is it?
Author(s)Linda Stocum, Associate Editor
Savina Aneja, MD, highlights the importance of Melanoma Monday and gives clinical pearls on how to counsel patients, skin cancer screenings, and more.
Advertisement
Savina Aneja, MD, a board-certified dermatologist in practice at Advance Dermatology and Cosmetic Surgery in Orlando, Florida, talks about Melanoma Monday, which is May 2, 2022. She highlights the most important part of a skin cancer screening, common misconceptions patients have regarding skin cancer, and much more in this interview.
Advertisement
Related to this article
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
4
Fall Clinical 2026: The Data and Expert Advice Shaping Dermatology Practice
5